The Evolving HER2+ Metastatic Breast Cancer Treatment Landscape

EP. 1: Treatment Landscape for HER2+ Metastatic Breast Cancer

ByAndrew D. Seidman, MD,Aditya Bardia, MD, MPH, FASCO,Mark D. Pegram, MD,Ruta Rao, MD

November 16th 2021

Panelists provide an overview of the treatment landscape for patients with HER2-positive metastatic breast cancer.

EP. 2: Treating Recurrent HER2+ Metastatic Breast Cancer Given Recent Clinical Trials

ByAndrew D. Seidman, MD,Aditya Bardia, MD, MPH, FASCO,Mark D. Pegram, MD,Ruta Rao, MD

November 16th 2021

A panel of experts reviews clinical trial data in recurrent HER2-positive metastatic breast cancer and discusses impacts on treatment selection.

EP. 3: Considerations for HER2+ mBC Management: Biomarkers and Bone Disease

ByAndrew D. Seidman, MD,Aditya Bardia, MD, MPH, FASCO,Mark D. Pegram, MD,Ruta Rao, MD

November 23rd 2021

Fielding questions from a live audience, experts discuss the lack of biomarkers in HER2+ metastatic breast cancer and how one might address progression of bone disease.

EP. 4: Patient Case #1: Frontline Therapy for HER2+ mBC

ByAndrew D. Seidman, MD,Aditya Bardia, MD, MPH, FASCO,Mark D. Pegram, MD,Ruta Rao, MD

November 23rd 2021

Using a patient case to center their discussion, the panel reviews frontline treatment options for HER2+ metastatic breast cancer and the rationale behind selection.

EP. 5: Patient Case #1: Second-Line Therapy for HER2+ mBC

ByAndrew D. Seidman, MD,Aditya Bardia, MD, MPH, FASCO,Mark D. Pegram, MD,Ruta Rao, MD

November 30th 2021

Moving to optimal treatment approaches in second-line therapy, experts close out a patient case of HER2+ metastatic breast cancer.

EP. 6: Patient Case #2: Third-Line Options for HER2+ mBC With Lung Disease

ByAndrew D. Seidman, MD,Aditya Bardia, MD, MPH, FASCO,Mark D. Pegram, MD,Ruta Rao, MD

November 30th 2021

In another patient case, panelists break down third-line therapy options for someone with HER2+ metastatic breast cancer and lung disease.

EP. 7: Audience Questions on Selecting Optimal Therapy for mBC

ByAndrew D. Seidman, MD,Aditya Bardia, MD, MPH, FASCO,Mark D. Pegram, MD,Ruta Rao, MD

December 8th 2021

Panelists field questions from a live audience regarding the optimal selection of therapy for patients with metastatic breast cancer.

EP. 8: Patient Case #3: Sequencing Therapy and Monitoring Results

ByAndrew D. Seidman, MD,Aditya Bardia, MD, MPH, FASCO,Mark D. Pegram, MD,Ruta Rao, MD

December 8th 2021

Centering their conversation on a patient case, experts discuss the sequencing and monitoring of therapy in patients with HER2+ metastatic breast cancer.